ReviewAdvances in rheumatology (London, England)2024
Unveiling the clinical spectrum of relapsing polychondritis: insights into its pathogenesis, novel monogenic causes, and therapeutic strategies.
Review in Advances in rheumatology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Calcified ears due to relapsing polychondritis.Wiener klinische Wochenschrift · 2026Article
- Isolated tracheobronchial inflammation with airway obstruction: a diagnostic challenge.EULAR rheumatology open · 2026Article
- Relapsing Polychondritis Associated With Primary Sjögren's Syndrome: A Rare Autoimmune Overlap.Cureus · 2026Article
- Pericardial patch tracheobronchoplasty for airway stenosis due to relapsing polychondritis.Indian journal of thoracic and cardiovascular surgery · 2025Article
- Clinical features and treatments of VEXAS syndrome in critical care: a scoping review.Critical care (London, England) · 2025Article
- A case to hear: Ears hard as rock.JAAD case reports · 2025Article
- Article
- Relapsing Polychondritis With Palmoplantar Pustulosis: A Case Report.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2025Article
- Respiratory-Predominant Relapsing Polychondritis: The Role of Pet Scan in Making this Challenging Diagnosis.European journal of case reports in internal medicine · 2025Article
- Article
- Relapsing Polychondritis-Associated Myocardial Infarction With Non-Obstructive Coronary Arteries.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapsing polychondritis is a rare multisystem disease involving cartilaginous and proteoglycan-rich structures. The diagnosis of this disease is mainly suggested by the presence of flares of inflammation of the cartilage, particularly in the ears, nose or respiratory tract, and more rarely, in the presence of other manifestations. The spectrum of clinical presentations may vary from intermittent episodes of painful and often disfiguring auricular and nasal chondritis to an occasional organ or even life-threatening manifestations such as lower airway collapse. There is a lack of awareness about this disease is mainly due to its rarity. In 2020, VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, a novel autoinflammatory syndrome, was described. VEXAS syndrome is attributed to somatic mutations in methionine-41 of UBA1, the major E1 enzyme that initiates ubiquitylation. This new disease entity connects seemingly unrelated conditions: systemic inflammatory syndromes (relapsing chondritis, Sweet's syndrome, and neutrophilic dermatosis) and hematologic disorders (myelodysplastic syndrome or multiple myeloma). Therefore, this article reviews the current literature on both disease entities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.